Progress in the design of low molecular weight thrombin inhibitors.
Intravascular thrombosis and its complication, embolism, is a leading cause of morbidity and mortality throughout the world. Past few decades have seen a great deal of progress in the development of antithrombotic agents, though the current treatment options are limited to heparin, LMW heparins, and warfarin. Detailed understanding of the biochemical and biophysical mechanisms of activation and regulation of blood coagulation have helped in developing specific inhibitors of enzymes, especially thrombin, within the coagulation cascade. Thrombin plays a central role in the coagulation cascade and so has become the primary target for the development of antithrombotic drugs. The review covers the main pharmacological aspects of haemostasis and thrombosis and provides an update on low molecular weight thrombin inhibitors along with the limitations of the prevalent antithrombotic agents. Recent developments in small molecule inhibitors of Protease Activated Receptor-1 (PAR-1) which can be helpful for the treatment of thrombotic and vascular proliferative disorders, have also been discussed.
Srivastava
Stuti
S
Medicinal Chemistry Division, Central Drug Research Institute, Lucknow, India.
Goswami
Lalit N
LN
Dikshit
Dinesh K
DK
D000818:Animals; D000991:Antithrombins / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects; D015195:Drug Design; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D008970:Molecular Weight; D013917:Thrombin / Q000502:physiology
D000991:Antithrombins; D013917:Thrombin